Palbociclib Intermediate CAS 1013916-37-4 Purity >99.0% (HPLC) Factory High Quality

Short Description:

Chemical Name: 2-Chloro-8-Cyclopentyl-5-Methyl-8H-Pyrido[2,3-d]pyrimidin-7-one

CAS: 1013916-37-4

Purity: >99.0% (HPLC)

Appearance: Faint Yellow Powder

Intermediate of of Palbociclib (CAS: 571190-30-2)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Palbociclib Related Intermediates:
Palbociclib CAS 571190-30-2
5-Bromo-2,4-Dichloropyrimidine CAS 36082-50-5
5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8
tert-Butyl 4-(6-Nitropyridin-3-yl)piperazine-1-Carboxylate CAS 571189-16-7
tert-Butyl 4-(6-Amino-3-Pyridyl)piperazine-1-Carboxylate CAS 571188-59-5
6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-one CAS 1016636-76-2
2-Chloro-8-Cyclopentyl-5-Methyl-8H-Pyrido[2,3-d]pyrimidin-7-one CAS 1013916-37-4

Chemical Properties:

Chemical Name	2-Chloro-8-Cyclopentyl-5-Methyl-8H-Pyrido[2,3-d]pyrimidin-7-one
Synonyms	2-Chloro-8-Cyclopentyl-5-Methylpyrido[2,3-d]pyrimidin-7(8H)-one; Palbociclib Intermediate 2
CAS Number	1013916-37-4
CAT Number	RF-PI1847
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C13H14ClN3O
Molecular Weight	263.72
Water Solubility	Slightly Soluble in Water
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Faint Yellow Powder
Purity / Analysis Method	>99.0% (HPLC)
Moisture (K.F)	<0.50%
Residue on Ignition	<0.20%
Total Impurities	<1.00%
Test Standard	Enterprise Standard
Usage	Intermediate of Palbociclib (CAS: 571190-30-2)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

2-Chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (CAS: 1013916-37-4) is used as a pharmaceutical intermediate of Palbociclib (CAS: 571190-30-2). Palbociclib is a drug for the treatment of ER-positive and HER2-negative breast cancer developed. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy by any organization, and as of December 2017 has been prescribed more than 90,000 times.